GRI Bio Inc.
GRI | NASDAQ
$1.53
-$0.04 (-2.55%)
At close: Oct 30, 2026, 4:00 PM ET
$1.52
-$0.01 (-0.65%)
After-hours:
Oct 30, 2026, 7:32 PM ET
-2.55%
(1D)No price chart data available for 1D timeframe.
Rating
29.2
-4.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #818/1028 (Top 80%)
Key Statistics
Market Data
Market Cap $3.34M
1D Range
1.49 1.59
52W Range
1.38 59.92
Valuation (TTM)
PE -0.04
PB 0.33
EV/EBITDA 0.78
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $18.50
Cash Flow
FCF Yield -311.5%
SBC Adj. FCF Yield -329.3%
SBC Impact -5.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 148.4% |
78.7%
FCF 3Y | 5Y 3.8% |
-21.2%
Returns
ROA -84.9%
ROE -134.0%
ROIC -93.8%
Financial Health
Net Cash
$10.9M
Current Ratio 10.30
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune diso...
Sector Healthcare
Industry Biotechnology
Employees 4
IPO Date Feb 10, 2021
Website www.gribio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$18.50
Upside
+1109.15%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GRI